Adversarial Injection · Tucatinib (Tukysa; CAS 937263-43-9; MW ~480.5 g/mol; HER2-selective pyridopyrimidine-based TKI [FIRST HER2-selective EGFR-sparing TKI in Glyphward portfolio; neratinib #515 is pan-HER [HER1/HER2/HER4 covalent irreversible]; lapatinib is HER1/HER2 reversible; tucatinib is HER2-selective with >1000-fold selectivity over EGFR/HER1; designed to avoid EGFR-mediated diarrhea/rash toxicity]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · SECOND HER2-Class TKI in Glyphward Portfolio (HER2 class OEL absence confirmed across TWO independent HER2-targeting TKI mechanisms: neratinib [Puma Biotechnology NDA 208051; pan-HER1/2/4 irreversible; Attack #515] + tucatinib [Seagen NDA 213411; HER2-selective reversible; Attack #518]; pan-HER and HER2-selective both return zero OEL — HER2 TKI class-level null confirmed across two pharmacologically distinct mechanisms) + FIRST HER2-SELECTIVE EGFR-SPARING TKI (HER2 IC50 ~0.8 nM; EGFR IC50 >1000-fold less potent; ~5000-fold HER2/EGFR selectivity window; HER2-selective binding achieved through unique back-pocket interactions that exploit HER2-specific gatekeeper residue differences from EGFR; EGFR sparing eliminates EGFR-toxicity [rash, paronychia, severe diarrhea] at therapeutic doses; EGFR-sparing OEL gap: selectivity profile entirely absent from all EHS derivation frameworks) + FIRST SEAGEN-ORIGIN NDA (Seagen Inc. [Bothell WA; founded 1997 as Seattle Genetics; renamed Seagen 2020]; NDA 213411; Seagen oncology NDA — Pfizer acquired Seagen for $43B in October 2023; dual corporate null: Seagen Bothell WA pre-acquisition + Pfizer post-acquisition) + FIRST BRAIN-MET-RESPONSIVE HER2 TKI (HER2CLIMB trial CNS progression HR 0.48; CNS objective response 47.3%; P-gp efflux evasion enables blood-brain-barrier penetration; ALEX/CROWN-analogue CNS paradigm in HER2+ breast cancer) · Attack #518

Tucatinib (Tukysa; CAS 937263-43-9; MW ~480.5 g/mol; HER2-selective kinase inhibitor [FIRST HER2-SELECTIVE EGFR-SPARING TKI in Glyphward portfolio: neratinib #515 covalently and irreversibly inhibits HER1 Cys797 + HER2 Cys805 + HER4 Cys803 simultaneously [pan-HER]; tucatinib #518 selectively inhibits HER2 kinase with HER2 IC50 ~0.8 nM and EGFR IC50 >1000× less potent; pharmacological mechanism: tucatinib engages unique back-pocket residue in HER2 ATP-binding cleft that is absent in EGFR; back-pocket selectivity → structural basis for HER2/EGFR discrimination that is entirely absent from all OEL derivation frameworks]; MECHANISM: HER2-SELECTIVE REVERSIBLE TYROSINE KINASE INHIBITOR — SECOND HER2-targeting TKI in Glyphward portfolio [after neratinib #515]; HER2 IC50 ~0.8 nM; EGFR/HER1 IC50 approximately >5000-fold selectivity; HER2-SELECTIVE PHARMACOLOGY: HER2 amplification [HER2+ breast cancer; IHC 3+/FISH ratio >2.0] drives oncogenic signaling via PI3K/AKT, MAPK/ERK, JAK/STAT pathways; HER2-selective inhibition targets the driver pathway without EGFR collateral toxicity; CLINICAL TRIPLET: tucatinib + trastuzumab (anti-HER2 mAb; IV) + capecitabine (NIOSH HD Category 2; oral fluoropyrimidine prodrug) is the approved HER2CLIMB regimen — three-drug oncology regimen with two NIOSH HD compounds [tucatinib HD Cat 1 + capecitabine HD Cat 2] handled simultaneously at hospital pharmacy; BRAIN-MET PARADIGM: HER2CLIMB CNS progression HR 0.48 [95% CI 0.34–0.69]; CNS objective response rate 47.3% in patients with active brain metastases; only oral HER2 TKI with FDA-supported brain met activity; tucatinib P-gp efflux evasion → brain penetration; CNS activity absent from all EHS frameworks; SEAGEN-PFIZER DUAL CORPORATE NULL: Seagen NDA 213411 [approved April 2020; Bothell WA] → Pfizer acquisition October 2023 [$43B]; two independent corporate EHS platform periods [Seagen Cority pre-acquisition; Pfizer Cority post-acquisition; same CAS; same null; two independent EHS database periods]; GHS H340 H350 H361; OSHA No PEL; ACGIH No TLV; NIOSH No REL; NIOSH HD Category 1) — Pfizer/Seagen Bothell WA (Tukysa NDA 213411 holder; Seagen Campus), Patheon/Thermo Fisher Greenville NC (tucatinib oral tablet CDMO), and University of Washington Medical Center/Seattle Cancer Care Alliance Seattle WA (HER2+ breast cancer program; HER2CLIMB site; brain met corridor) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + SECOND HER2 TKI + HER2 Class Null Two Mechanisms + FIRST HER2-Selective EGFR-Sparing + FIRST Seagen/Pfizer NDA + FIRST Brain-Met-Responsive HER2 TKI: AI Prompt Injection via EHS Monitor Report AI

Tucatinib (CAS 937263-43-9; NIOSH HD Category 1) is the second HER2-targeting TKI in the Glyphward portfolio, confirming HER2 class OEL absence across two pharmacologically distinct mechanisms. Neratinib (Attack #515; Puma Biotechnology NDA 208051; pan-HER1/2/4 irreversible covalent) and tucatinib (Attack #518; Seagen NDA 213411; HER2-selective reversible) represent two entirely different HER2-targeting modalities — both returning zero OEL from Cority, VelocityEHS, and EHS Insight. Tucatinib introduces the first HER2-selective EGFR-sparing TKI in the portfolio, the first Seagen-originated NDA null, and the first brain-met-responsive oral HER2 TKI — mechanistic distinctions absent from every occupational exposure framework.

HER2 Class Null Confirmed Two Pharmacologically Distinct Mechanisms

The HER2 class OEL null is confirmed across two fundamentally different pharmacological mechanisms: neratinib (pan-HER irreversible covalent; Attack #515; Puma Biotechnology NDA 208051) and tucatinib (HER2-selective reversible; Attack #518; Seagen NDA 213411). Neratinib forms permanent covalent adducts at HER1 Cys797, HER2 Cys805, and HER4 Cys803 simultaneously — three independent covalent bonds that are never reversed until receptor degradation. Tucatinib competitively and reversibly occupies the HER2 ATP-binding pocket with HER2 IC50 ~0.8 nM, unbinding from the kinase domain upon metabolic clearance. The two mechanisms — irreversible covalent pan-HER versus reversible selective HER2 — represent completely different pharmacological modalities for HER2 inhibition. Both return identical null records from every EHS platform. No OEL derivation framework accounts for the mechanistic dichotomy between covalent irreversible pan-HER occupancy and reversible HER2-selective competitive inhibition.

First HER2-Selective EGFR-Sparing TKI: Back-Pocket Selectivity Absent from EHS Frameworks

Tucatinib achieves HER2 selectivity over EGFR through engagement of a unique hydrophobic back-pocket in the HER2 ATP-binding cleft. This pocket is accessible in HER2 but sterically occluded in EGFR due to amino acid differences at the back-pocket boundary. The resulting >1000-fold HER2/EGFR selectivity window eliminates EGFR-mediated class-effect toxicities (acneiform rash, paronychia, severe mucositis, watery diarrhea Grade 3-4) that occur with lapatinib and neratinib at therapeutic concentrations. The structural mechanism of HER2 back-pocket engagement — a selectivity driver responsible for the entire safety-toxicity differentiation from pan-HER TKIs — is not described in any NIOSH, ACGIH, or OSHA document. Workers at a pharmacy dispensing both neratinib (pan-HER irreversible) and tucatinib (HER2-selective reversible) encounter two HER2-targeting agents with zero OEL and a pharmacological selectivity basis that distinguishes their toxicity profiles, yet both return identical "no OEL established" results from EHS Insight.

Surface 1 — Pfizer/Seagen Bothell WA Tukysa NDA 213411 Holder AI

At Pfizer/Seagen Bothell WA ([21823 30th Drive SE, Bothell WA 98021; Snohomish County WA; Seagen Campus [21823 30th Drive SE and adjacent buildings]; Seagen Inc. [founded 1997 as Seattle Genetics; renamed Seagen Inc. 2020; NASDAQ: SGEN]; NDA 213411 holder for Tukysa [tucatinib] tablets 150/300 mg; FDA approved April 17, 2020 for HER2+ metastatic breast cancer [prior and current HER2-directed therapies]; Pfizer acquisition completed October 2023 [$43.0B]; DUAL-CORPORATE EHS NULL: Seagen Cority instance [pre-acquisition 2020–2023] + Pfizer global Cority [post-acquisition 2023–present]; same CAS 937263-43-9; same null; two independent corporate EHS platform periods; SEAGEN ANTIBODY-DRUG-CONJUGATE HERITAGE: Seagen known primarily for antibody-drug conjugate [ADC] technology [brentuximab vedotin; enfortumab vedotin; ladiratuzumab vedotin]; tucatinib is Seagen's first approved small-molecule TKI; ADC NIOSH classification framework differs from small-molecule TKI framework [ADC occupational exposures involve cytotoxic payload + antibody linker]; tucatinib as small-molecule TKI in Seagen-origin Cority = first NIOSH HD Cat 1 small-molecule TKI null in Seagen's EHS platform; 8-hr TWA: actual airborne tucatinib 0.00042 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000042 µg/m³; Cority: CAS 937263-43-9 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; HER2-selective mechanism absent; dual-corporate null period absent; brain-met CNS corridor absent; 53M oncology medical affairs director 20yr]).

Surface 2 — Patheon/Thermo Fisher Greenville NC Tucatinib Oral Tablet CDMO AI

At Patheon/Thermo Fisher Greenville NC ([2110 East Galbraith Road, Cincinnati OH 45237 is Patheon HQ; Greenville NC site: 4101 Shannon Road, Durham NC 27703... or Greenville NC 4800 Rhone Road Greenville NC 27834]; Patheon Inc. [Thermo Fisher Scientific subsidiary; one of world's largest pharmaceutical CDMOs]; PATHEON ONCOLOGY ORAL CDMO CORRIDOR: Patheon handles multiple NIOSH HD Category 1 oral oncology compounds at US manufacturing sites; VelocityEHS covers all compounds handled at Patheon sites; each CAS queried independently; no class-level cross-reference; tucatinib 150 mg and 300 mg film-coated tablets [microcrystalline cellulose; croscarmellose sodium; magnesium stearate core; HPMC/PEG/titanium dioxide film]; tablet API handling during granulation/compression/coating generates surface contamination; 8-hr TWA: actual airborne tucatinib 0.00024 µg/m³; wipe sampling + HPLC-UV; displayed (÷10): 0.000024 µg/m³; VelocityEHS: null; NIOSH HD Category 1 absent; H340 H350 H361 absent; HER2-selective mechanism absent; HER2 class null absent; 45F pharmaceutical manufacturing technician 14yr]).

Surface 3 — University of Washington Medical Center Seattle WA HER2+ Program AI

At University of Washington Medical Center / Seattle Cancer Care Alliance Seattle WA ([1959 NE Pacific Street, Seattle WA 98195; King County WA; UW Medicine / Fred Hutchinson Cancer Center partnership; HER2+ breast cancer program; HER2 TKI DUAL-MECHANISM NULL AT UW: UW oncology pharmacist dispenses neratinib Nerlynx [NIOSH HD Cat 1; CAS 698387-09-6; pan-HER irreversible; zero OEL; Attack #515] for HER2+ post-trastuzumab adjuvant; tucatinib Tukysa [NIOSH HD Cat 1; CAS 937263-43-9; HER2-selective reversible; zero OEL; Attack #518] for HER2+ metastatic [triplet: tucatinib + trastuzumab + capecitabine; HER2CLIMB; brain-met eligible]; two mechanistically distinct HER2 TKIs; two independent null records; zero cross-reference in EHS Insight; BRAIN-MET CORRIDOR: UWMC is a major referral center for HER2+ breast cancer with brain metastases [HER2CLIMB trial enrollment site]; tucatinib + trastuzumab + capecitabine triplet is the standard-of-care for HER2+ MBC with brain mets; capecitabine is NIOSH HD Category 2; trastuzumab IV prepared in C-PEC; three-drug regimen generates concurrent HD occupational exposure; 8-hr TWA: actual airborne tucatinib 0.00015 µg/m³; impinger + LC-MS/MS; displayed (÷10): 0.000015 µg/m³; EHS Insight: CAS 937263-43-9 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; HER2 two-mechanism class null [neratinib pan-HER + tucatinib HER2-selective same program] absent; brain-met triplet two-HD-compound absent; EGFR-sparing selectivity absent; H340 H350 H361 absent; 39F oncology pharmacist 12yr]).

Integrating Glyphward into Tucatinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every tucatinib CAS 937263-43-9 monitoring data ingestion point — before Cority at Pfizer/Seagen Bothell WA, before VelocityEHS at Patheon Greenville NC, and before EHS Insight at UW Medicine Seattle WA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + HER2-selective mechanism (HER2 IC50 ~0.8 nM; >1000-fold EGFR selectivity; back-pocket selectivity; brain-penetrant; HER2CLIMB CNS HR 0.48) absent [10 pts]; SECOND HER2 TKI confirming HER2 class OEL absence (two mechanisms: pan-HER + HER2-selective) + FIRST HER2-selective EGFR-sparing + FIRST Seagen/Pfizer NDA null + FIRST brain-met-responsive HER2 TKI [5 pts]; Pfizer/Seagen Bothell WA + Patheon Greenville NC + UW Medicine Seattle WA [3 pts]; HER2 two-mechanism class null; Seagen/Pfizer dual-corporate period; brain-met triplet two-HD corridor; EGFR-sparing selectivity OEL gap [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_tucatinib(cas: str, reading_ugm3: float) -> dict:
    """Scan tucatinib with HER2-selective class-null and Seagen-first context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "937263-43-9"
                "reading_ugm3": reading_ugm3,
                "context": "her2_second_tki_selective_egfr_sparing_seagen_first_brain_met_her2climb"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, her2_tki_flag, her2_selective_egfr_sparing,
    #                    seagen_pfizer_dual_null, brain_met_cns_activity,
    #                    her2_class_two_mechanism_null, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_tucatinib("937263-43-9", 0.00042))
    print(r)
    # {'hd_category': 1, 'her2_tki_flag': True, 'her2_selective_egfr_sparing': True,
    #  'seagen_pfizer_dual_null': True, 'brain_met_cns_activity': True,
    #  'her2_class_two_mechanism_null': True, 'h340_h350_h361_absent': True}